Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Questcor Pharmaceuticals, Inc.
NEW YORK, Sept. 24, 2012 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Questcor Pharmaceuticals, Inc. ("Questcor" or the "Company") (NasdaqGS: QCOR -News), concerning potential violations of federal securities laws.
Questcor fell as much as 22 percent after disclosing the company's marketing practices are being investigated by the U.S. government. Also Questcor plunged the most in 20 years last week after insurer Aetna Inc. said it would limit coverage of Questcor's top-selling drug, H.P. Acthar, a treatment for multiple sclerosis and infant seizures. Aetna issued a Clinical Policy Bulletin stating that based on review of medical studies, Acthar was "not medically necessary" for several conditions for which it has been prescribed.
If you are aware of any facts relating to this investigation, or purchased shares of Questcor, you can assist this investigation by contacting either Peretz Bronstein or Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman, 212-697-6484
[email protected]
SOURCE Bronstein, Gewirtz & Grossman, LLC
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article